Zobrazeno 1 - 10 of 12 pro vyhledávání: '"N. A. Malamos"'
1
Irinotecan combined with docetaxel in pre-treated metastatic breast cancer patients: a phase II study
Autor: N. Pergantas, George P. Stathopoulos, J. Stathopoulos, Ch. Kosmas, D. Tsavdaridis, S. K. Rigatos, N. A. Malamos, J. Xynotroulas
Publikováno v: Cancer Chemotherapy and Pharmacology. 56:487-491
Purpose: This is a phase II study where a novel chemotherapy combination was tested in pre-treated breast cancer patients: docetaxel and irinotecan have already been established as agents for breast and colorectal cancer, respectively. Methods: Forty
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2b1648ea46f6908b8caef4ce2a7039e
https://doi.org/10.1007/s00280-005-1006-3
Zobrazit plný text záznamu
2
Phase I–II study of docetaxel and ifosfamide combination in patients with anthracycline pretreated advanced breast cancer
Autor: Niki Stavroyianni, Christos Kosmas, Aristidis Polyzos, Sofia Rokana, N. A. Malamos, A. Gregoriou, N. Tsavaris
Publikováno v: British Journal of Cancer
Given the established individual activity of docetaxel and ifosfamide in anthracycline pretreated advanced breast cancer, the present phase I-II study aimed to define the maximum tolerated dose (MTD), the dose-limiting toxicities (DLTs), and activity
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6650fb11c1d0e398485439cbdf240209
http://europepmc.org/articles/PMC2747562
Zobrazit plný text záznamu
3
Phase I study of dose-escalated paclitaxel, ifosfamide, and cisplatin (PIC) combination chemotherapy in advanced solid tumours
Autor: M. J. Antonopoulos, N. A. Malamos, M Katsikas, Christos Kosmas, Aristidis Polyzos, N. Tsavaris
Publikováno v: British Journal of Cancer
Based on the already known in vitro synergy between paclitaxel (taxol), cisplatin and oxazophosphorine cytostatics and the broad spectrum of activity of the above drugs we sought to evaluate the paclitaxel (taxol)-ifosfamide-cisplatin (PIC) combinati
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac910dc4479cf5512657b48d12238f5a
https://doi.org/10.1054/bjoc.1999.0919
Zobrazit plný text záznamu
4
Evaluation of the paclitaxel-ifosfamide-cisplatin (TIP) combination in relapsed and/or metastatic cervical cancer
Autor: Kosmas, C. Mylonakis, N. Tsakonas, G. Vorgias, G. and Karvounis, N. Tsavaris, N. Daladimos, T. Kalinoglou, N. and Malamos, N. Akrivos, T. Karabelis, A.
BACKGROUND: Recurrent or metastatic cervical cancer represents an aggressive malignancy with a high rate of locoregional and distant failure. Therefore, we evaluated the three-drug combination of paclitaxel-ifosfamide-cisplatin ( TIP). METHODS: Syste
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::d33e9805f7b98ca95475ae0140d62846
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3143457
Zobrazit plný text záznamu
6
Weekly administration of topotecan-paclitaxel as second-line treatment in ovarian cancer
Autor: C. Christodoulou, N. A. Malamos, D.V. Skarlos, J. Stathopoulos, Gerassimos Aravantinos, S. K. Rigatos, George P. Stathopoulos
Publikováno v: Cancer chemotherapy and pharmacology. 60(1)
To investigate the weekly administration of topotecan combined with paclitaxel in pretreated advanced ovarian cancer patients; our objectives were to determine efficacy, toxicity and survival.The chemotherapy agents, topotecan and paclitaxel were adm
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bab03da067474139f31cbe53e61714b
https://pubmed.ncbi.nlm.nih.gov/17111119
Zobrazit plný text záznamu
7
Weekly administration of topotecan and paclitaxel in pretreated advanced cancer patients: a phase I/II study
Autor: J. Stathopoulos, Filippos Deliyiannis, George P. Stathopoulos, S. K. Rigatos, Christos Christodoulou, Dimosthenis Skarlos, N. A. Malamos
Publikováno v: Cancer chemotherapy and pharmacology. 54(3)
This study was a phase I/II, cohort, dose-escalation trial of topotecan and paclitaxel. Its aim was to determine the dose-limiting toxicity (DLT) of the combination and to define the maximum tolerated dose (MTD), as a recommended dose for phase II, a
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ea11ab3345a5323c9734b96faaa53a4
https://pubmed.ncbi.nlm.nih.gov/15127231
Zobrazit plný text záznamu
8
Chemotherapy-induced complete regression of choroidal metastases and subsequent isolated leptomeningeal carcinomatosis in advanced breast cancer: a case report and literature review
Autor: C, Kosmas, N A, Malamos, N, Tsavaris, M, Antonopoulos
Publikováno v: Journal of neuro-oncology. 47(2)
Choroidal metastases from breast cancer represent an unusual metastatic presentation that has been traditionally treated with radiation therapy. Herein, we report a case of metastatic breast cancer presenting with pulmonary, cutaneous, lymph node and
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::3564f51b923ef2d99a64ef3ee0f2873f
https://pubmed.ncbi.nlm.nih.gov/10982158
Zobrazit plný text záznamu
10
Paclitaxel combined with cis-platin as second-line treatment in patients with advanced non-small cell lung cancers refractory to cis-platin
Autor: S. K. Rigatos, N. A. Malamos, George P. Stathopoulos
Publikováno v: Oncology reports. 6(4)
We combined paclitaxel with cis-platin as second-line treatment in patients with non-small cell lung cancer (NSCLC) who had previously undergone first-line therapy with cis-platin combined with cytotoxic drugs other than taxanes. The aim was to evalu
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6816a97238e894b9b57d5cf1982c032f
https://pubmed.ncbi.nlm.nih.gov/10373659
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje